

05-20-2003

10/333286



DT17 Rec'd PCT/PTC 17 JAN 2003

Form PTO-1595 (Rev. 10/02)		102451632 RECORDATION FORM COVER SHEET		U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office	
OMB No. 0651-0027 (exp. 6/30/2005)		PATENTS ONLY		1103326-0708	
Tab settings ⇌ ⇌ ⇌ ▼ ▼ ▼ ▼ ▼ ▼ ▼					
To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.					
1. Name of conveying party(ies): BERGSTROM, Per-Olov HEDBERG, Martin LINDSTROM, Mona STAHL, Erica Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			2. Name and address of receiving party(ies) Name: <u>AstraZeneca AB</u> Internal Address: _____ _____ Street Address: <u>S-151 85</u> _____ City: <u>Sodertalje</u> <u>Sweden</u> Zip: _____ State: <u>SECC</u> COUNTRY Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other _____					
Execution Date: <u>Dec. 3, Dec. 3, Dec. 13, and</u> <u>Dec. 3, 2002, respectively</u>					
4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: _____ A. Patent Application No.(s) B. Patent No.(s) Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			16333286		
5. Name and address of party to whom correspondence concerning document should be mailed: Name: <u>White & Case LLP</u> Internal Address: <u>Patent Department</u> _____ <u>1155 Avenue of the Americas</u> Street Address: _____ _____ City: <u>NY</u> State: <u>NY</u> Zip: <u>10036</u>			6. Total number of applications and patents involved: <u>1</u> 7. Total fee (37 CFR 3.41).....\$ <u>40</u> <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account 8. Deposit account number: <u>23-1703</u> (Attach duplicate copy of this page if paying by deposit account)		
DO NOT USE THIS SPACE					
9. Statement and signature. <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i> <u>Andrew Fessak, Reg. No. 48,528</u> <u>Andrew Fessak</u> <u>Jan. 17, 2003</u> Name of Person Signing Signature Date Total number of pages including cover sheet, attachments, and documents: <u>5</u>					

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

ASSIGNMENT

WHEREAS, we, BERGSTRÖM, Per-Olov; HEDBERG, Martin; LINDSTRÖM, Mona; and STÄHLE, Erica, all of AstraZeneca R&D Södertälje, S-151 85 Södertälje, Sweden; citizens of Sweden, have made an invention entitled NOVEL FORM OF (R)-N-[5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-2-NAPHTHYL]-4-MORPHOLINOBENZAMIDE for which a PCT-application has been filed on 17 July 2001 with application No. PCT/SE01/01643, which application claims priority from Swedish application No. 0002729-2 filed on 20 July 2000, and for which we are about to make an application for Letters Patent of the United States; and

WHEREAS, **AstraZeneca AB**, a corporation organized and existing under the laws of **Sweden** and having an office for the transaction of business in Södertälje, Sweden, is desirous of acquiring the entire right, title and interest in and to said invention and any improvements thereon, and in and to the said application for Letters Patent there for, and any Letters Patent which may be obtained therefor;

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN, BE IT KNOWN, that we, the said INVENTORS, for and in consideration of the sum of One Dollar (\$1.00), lawful money of the United States, to us in hand paid by said ASSIGNEE, and other valuable considerations unto us moving from said ASSIGNEE, at or before the ensealing and delivery of these presents, the receipt of which is hereby acknowledged, have sold, assigned, transferred and conveyed and by these presents do sell, assign, transfer and convey, unto said ASSIGNEE, its successors and assigns, the entire right, title and interest in and to the said invention as set forth and described in the specification forming a part of the application for Letters Patent of the United States for NOVEL FORM OF (R)-N-[5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-2-NAPHTHYL]-4-MORPHOLINOBENZAMIDE and any and all improvements thereon, and in and to said application and any division, continuation or continuation-in-part thereof, and in and to any Letters Patent of the United States which may be issued on any of said applications, and any reissues thereof, and in and to any and all applications for Letters Patent filed in foreign countries for said invention or improvements, including all priority rights under the Paris Convention, and any and all Letters Patent which may be granted in foreign countries therefor, TO HAVE AND TO HOLD THE SAME to the full end of the term or terms for which any and all said Letters Patent may be granted;

AND we, the said INVENTORS, do hereby authorize and request the Commissioner of Patents and Trademarks to issue the said Letters Patent of the United States to said ASSIGNEE, as the assignee of the entire right, title and interest in and to the same, for the sole use and behoof of said ASSIGNEE, its successors and assigns;


AND we, the said INVENTORS, for the considerations aforesaid, do hereby covenant and agree to and with said ASSIGNEE, its successors and assigns, that we have the full power to make this assignment, and that the rights assigned are not encumbered by any grant, license or right heretofore given, and that we, our executors or administrators, shall and will do all lawful acts and things and make, execute and deliver without further compensation, any and all other instruments in writing, further applications, papers, affidavits, powers of attorney, assignments, and other documents which, in the opinion of counsel for said ASSIGNEE, its successors and assigns, may be required or necessary to more effectively secure to and vest in said ASSIGNEE, its successors and assigns, the entire right, title and interest in and to said invention and improvements, applications, Letters Patent, rights, benefits, privileges and advantages hereby sold, assigned, transferred and conveyed, and that we will sign any applications for reissue which may be desired by the owner of the patent or patents which may be issued for the said invention or improvements.


IN WITNESS WHEREOF, we, the said INVENTORS, have hereunto set our hands and sealson the date below written.

3 December 2002
Date


By: Per-Olov Bergström

WITNESS:


Signature of Witness


Signature of Witness

Name and Address of Witness:

Inger Bonnevier
AstraZeneca AB
S-151 85 Södertälje
Sweden

Name and Address of Witness:

Kerstin Andersson
AstraZeneca AB
S-151 85 Södertälje
Sweden

(NOTE: The name and address of each witness should be typed or clearly printed below the signature of the witness.

3 December 2002

Date


By: Martin Hedberg

WITNESS:


Signature of Witness

Name and Address of Witness:

Inger Bonnevier
AstraZeneca AB
S-151 85 Södertälje
Sweden


Signature of Witness

Name and Address of Witness:

Kerstin Andersson
AstraZeneca AB
S-151 85 Södertälje
Sweden

(NOTE: The name and address of each witness should be typed or clearly printed below the signature of the witness.

20021213
Date


By: Mona Lindström

WITNESS:


Signature of Witness

Name and Address of Witness:

Dan Eriksson
Luleåvägen 199
857 31 Sundsvall


Signature of Witness

Name and Address of Witness:

Carina Eriksson
Medborgargatan 79
856 31 Sundsvall


(NOTE: The name and address of each witness should be typed or clearly printed below the signature of the witness.


3 December 2002

Date

By: Erica Ståhle

WITNESS:


Signature of Witness


Signature of Witness

Name and Address of Witness:

Inger Bonnevier
AstraZeneca AB
S-151 85 Södertälje
Sweden

Name and Address of Witness:

Kerstin Andersson
AstraZeneca AB
S-151 85 Södertälje
Sweden

(NOTE: The name and address of each witness should be typed or clearly printed below the signature of the witness.